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We proﬁled receptor tyrosine kinase pathway activation and key gene mutations in eight human lung tumor cell lines and 50
human lung tumor tissue samples to deﬁne molecular pathways. A panel of eight kinase inhibitors was used to determine whether
blocking pathway activation aﬀected the tumor cell growth. The HER1 pathway in HER1 mutant cell lines HCC827 and H1975
were found to be highly activated and sensitive to HER1 inhibition. H1993 is a c-MET ampliﬁed cell line showing c-MET and
HER1 pathway activation and responsiveness to c-MET inhibitor treatment. IGF-1R pathway activated H358 and A549 cells are
sensitivetoIGF-1Rinhibition.ThedownstreamPI3Kinhibitor,BEZ-235,eﬀectivelyinhibitedtumorcellgrowthinmostofthecell
lines tested, except the H1993 and H1650 cells, while the MEK inhibitor PD-325901 was eﬀective in blocking the growth of KRAS
mutated cell line H1734 but not H358, A549 and H460. Hierarchical clustering of primary tumor samples with the corresponding
tumor cell lines based on their pathway signatures revealed similar proﬁles for HER1, c-MET and IGF-1R pathway activation and
predict potential treatment options for the primary tumors based on the tumor cell lines response to the panel of kinase inhibitors.
1.Introduction
Lung cancer is the leading cause of cancer-related deaths
worldwide, resulting in 1.61 million new cases and 1.38
million deaths per year according to the Global cancer
statistics estimation in 2011 [1]. Lung cancer is generally
classiﬁed histologically into two major types, small cell lung
cancer (SCLC) and nonsmall cell lung cancer (NSCLC).
Approximately 85–90% of lung cancers are NSCLC repre-
senting three major subtypes based on tumor cell size, shape,
and composition, with adenocarcinoma accounting for 40%,
squamous cell lung carcinoma 25–30%, and large-cell lung
carcinoma accounting for 10–15% of all lung cancers [2, 3].
Although less than optimal, current conventional treatment
for lung cancer consists of surgery for operable candidates
and chemotherapy for disease-advanced patients with the
mean survival for most advanced lung cancer patients less
than one year [4]. During the last decade, considerable
progress has been made in the treatment of NSCLC due
to the emergence of new targeted therapies speciﬁc to
the oncogenic tyrosine kinase pathways activated in tumor
cells. For example, two epidermal growth factor receptor
(HER1) tyrosine kinase inhibitors (TKI), Geﬁtinib (Iressa)
and Erlotinib (Tarceva), have been FDA approved for the
treatment of locally advanced or metastatic NSCLC that
has failed at least one prior chemotherapy regimen [5, 6].
Other receptor tyrosine kinase (RTK) pathway inhibitors,
such as Sunitinib (Sutent), which targets the platelet-derived
growth factor receptors and vascular endothelial growth
factor receptors, as well as Crizotinib, a hepatocyte growth
factor RTK inhibitor, are in advanced clinical trials for
NSCLC [7, 8].
The advances made in targeted therapy for NSCLC are
based on understanding the mechanism by which mutated
genes confer a neoplastic phenotype on tumor cells and how
the targeted interruption of these oncogenic pathways leads
to clinical response. Thus, analysis of a pathway-focused
panel of biomarkers in fresh tumor tissue samples collected2 International Journal of Proteomics
from patients could pave the way for determining if the
markers are associated with the optimal clinical therapy
and may provide predictive value in identifying responsive
patients. In addition, drug combinations targeted against
the receptors aﬀecting downstream signaling molecules may
overcome pathway activation and drug resistance often seen
in NSCLC therapy. Diﬃculties in predicting eﬃcacy in
targeted therapy is due to the limited knowledge of the
activated oncogenic pathways in the patient’s tumor so
that the appropriate inhibitor(s) are not prescribed. Thus,
preclinicalcellularresponseproﬁlingoftumortissuesamples
has become a cornerstone in the development of novel
cancer therapeutics. To this end, we have developed and
trademarked a channel enzyme enhanced reaction (CEER)
assay methodology to proﬁle some of the major oncogenic
pathways activated in cancer cells and have used this
assay together with genotyping to characterize the activated
oncogenic pathways in eight human NSCLC tumor cell lines
as well as 50 fresh-frozen NSCLC samples collected from
patients. The aim of this study was to assess the potential
to prospectively classify lung cancer patients into diﬀerent
treatment groups based on correlation of pathway activation
proﬁles,genemutationalstatus,andclinicalfeaturesbetween
the patient tumor samples and the tumor cell lines. In
addition, we evaluated the eﬃcacy of a panel of eight kinase
pathway inhibitors to block the pathway activation and
proliferation of these eight lung tumor cell lines and used the
results to identify treatment options for the 50 lung cancer
patients.
2.MaterialsandMethods
2.1. Human Lung Tumor Cell Lines, Lung Cancer Tissue Sam-
ples, and Kinase Inhibitors. Eight NSCLC cell lines, HCC827,
H1975, H1734, H1993, H358, H1650, A549, and H460,
were selected, and they represent the major NSCLC cancer
subtypes, adenocarcinoma and large-cell lung carcinoma.
The cell lines were purchased from ATCC (Table 1). Fifty
lung adenocarcinomas samples were collected from patients
operated on for lung cancer at the University of Michigan.
Collection and use of all tissue samples were approved by
the Human Subjects Institutional Review Boards of the
UniversityofMichigan.Thedemographicinformationofthe
patients is shown in Supplementary Table 1. The primary
tumor samples were snap frozen and cryostat-sectioned
to identify regions representing >70% tumor cellularity
for subsequent pathway analysis. The samples (∼2c u b i c
millimetersinsize)wereshippedtoPrometheusLaboratories
on dry ice for analysis. Eight kinase inhibitors representing
a diverse panel of potential cancer therapeutics were pur-
chased from Selleck Chemicals (Houston, TX). The collec-
tion included speciﬁc as well as multiple RTK inhibitors,
that is, compounds targeting the cellular kinase pathways:
HER1/2/4 (epidermal growth factor receptors) inhibitors
(Erlotinib for HER1, Lapatinib for HER1/2, Geﬁtinib for
HER1/2/4, and BIBW-2992 is an irreversible inhibitor
for HER1/2); c-MET (hepatocyte growth factor receptor)
inhibitor, PF-2341066; IGF-1R (insulin-like growth factor-
1 receptor) inhibitor BMS-536924; MEK (mitogen-activated
protein kinase kinase) inhibitor, PD-325901, and PI3K
(phosphatidylinositol-3-kinase) and mTOR (mammalian
target of rapamycin) inhibitor BEZ-235.
2.2. Preparation of Lysates from Cell Lines and Primary
TumorSamples. Tumorcellswereculturedintheirrespective
growth medium recommended by ATCC plus 10% fetal
bovine serum (FBS). Cells were grown in 35mm 6-well cell
culture plates until reaching 80% conﬂuence. After washing
the cells with phosphate buﬀered saline (PBS) 3 times, the
cell culture plate was placed on ice and then the plate was
carefully tilted on its side for 10sec to completely remove
all residual media. Then, 150µL of ice cold lysis buﬀer was
added to each plate and the plate was then left on ice for
5 m i n .T h el y s e dc e l l sw e r es c r a p e do ﬀ and together with
the crude lysate transferred to a 1.5mL centrifuge tube. The
mixture was vortexed in the tube, placed on ice for 15min
and then centrifuged at 14,000rpm for 15min at 4◦C. The
supernatant was transferred to another centrifuge tube and
stored at −70◦C until analysis. The frozen tumor samples
were similarly processed by the addition of 4 volumes of
ice-cold lysis buﬀer per tissue volume and homogenized
in a Powergren High Throughput Homogenizer (Fisher
Scientiﬁc) at a speed setting of 7 for 2min. The homogenate
was transferred to a 1.5mL centrifuge tube and centrifuged
at 14,000rpm for 15min, at 4◦C. The supernatant from
the tumor lysate was harvested and stored at −70◦C until
analysis.
2.3. Proﬁling of Signaling Pathways Using the CEER Assay in
Tumor Cell Lines and Tissue Samples. The principle of the
CEER assay is based on the capture of the target protein
by a target-speciﬁc antibody printed in two dilutions on the
surface of a microarray slide. Measurement of the activation
status of the captured target protein is revealed by the
formation of a unique immunocomplex, requiring the colo-
calization of two detecting enzyme-conjugated antibodies
on the same target protein captured on the microarray
surface as illustrated in Supplemental Figure 1. Formation
of this complex is initiated by the binding of the ﬁrst
detecting antibody, which is coupled to glucose oxidase
(GO), to an epitope on the captured target protein that
is diﬀerent from the epitope recognized by the capture
antibody, followed by the binding of a second detecting
antibody, which is coupled to horseradish peroxidase (HRP),
to a phosphorylated tyrosine (p-Tyr) residue on the target
protein. Upon the addition of glucose, the immobilized GO
on the captured target protein produces H2O2 and due to the
close proximity, the locally generated H2O2 is then utilized
by the HRP coupled to the p-Tyr-speciﬁc second detecting
antibody to generate a chemical signal that can be ampliﬁed
with biotinyl-tyramide. The sensitivity and speciﬁcity for the
detection of the phosphorylated target protein are greatly
enhanced by this collaborative reaction and ampliﬁcation
process, which is mediated by the simultaneous binding of
three diﬀerent antibodies on the same target protein [9]( f o r
details of the CEER assay method to proﬁle the tumor cell
lines and tissue samples see Supplemental Methods).International Journal of Proteomics 3
Table 1: Clinical features of the eight lung tumor cell lines.
Name ATCC Cat. no. Type Source
HCC827 CRL-2868 Adenocarcinoma Primary, lung epithelial
H1975 CRL-5908 Adenocarcinoma Primary, lung epithelial
H1734 CRL-5891 Adenocarcinoma Primary, lung epithelial
H1993 CRL-5909 Adenocarcinoma Metastatic, lymph node
H358 CRL-5807 Bronchioalveolar carcinoma Primary, lung epithelial
H1650 CRL-5883 Bronchioalveolar carcinoma Metastatic, pleural eﬀusion
A549 CCL-185 Adenocarcinoma Primary, lung epithelial
H460 HTB-177 Large-cell carcinoma Metastatic, pleural eﬀusion
2.4. Inhibition of Activated Signaling Pathways in Tumor Cell
Lines by Kinase Inhibitors. T h et u m o rc e l l sw e r ec u l t u r e di n
their respective growth medium with 10% FBS in 35mm 6-
well cell culture plates until they reached ∼80% conﬂuence.
The cells were then starved overnight in serum-free medium,
followed by a 4-hour treatment with various concentrations
of the kinase inhibitor. Afterwards, cell lysates were prepared
from the treated cells as before and aliquots of the lysates
subjected to the CEER assay.
2.5. Inhibition of Tumor Cell Line Growth by Kinase Inhibitors.
The tumor cells were seeded into 96-well cell culture plates
and maintained in culture for 24 hours. After washing, the
cultured cells were incubated in their respective medium
containing 5% FBS and various concentrations of the
indicated inhibitor for 48hr. Determination of tumor cell
growth inhibition was performed by adding 100µL of the
combined Cell Titer-Glo Buﬀer and Cell Titer-Glo Substrate
Labeling Reagent (Promega) to each well of the plates,
followed by incubation at room temperature for 10min
to stabilize the luminescence. The luminescent signal from
the cell samples was detected by using an M5 microtiter
plate reader. For studies involving treatment with more than
one inhibitor, the selected inhibitor that showed more than
25% inhibition of tumor cell growth at 10µM concentration
when treated individually was further tested in combination
treatment with another inhibitor. A 5µM concentration of
each inhibitor was combined to make a 10µMd o s e ,a n d
the same half log dilution was made as in the single drug
treatmentforaddingtothecells.Tumorcellsweretreatedfor
48hrandcellviabilitywasmeasuredasinthesingleinhibitor
treatment.
2.6. Anchorage-Independent Inhibition of Tumor Cell Line
Growth by Kinase Inhibitors. A single cell suspension of 3000
cells from each of the eight tumor cell lines in 1mL mixture
of1.2%Agarose(Seaplaque;FMC,Rockland,ME)inDMEM
(Life Technologies, Carlsbad, CA) plus 10% FBS was added
on top of 1% soft agarose that had been allowed to gel
previously in the wells of a 35mm 6-well cell culture plate.
T h ep l a t e sw e r ek e p ta t4 ◦C for 2hr to solidify the cell-
containing layer. The plates were then incubated at 37◦Ci n
aC O 2 incubator with 2mL of medium containing various
concentrations of the kinase inhibitor. The medium with
the inhibitor was changed every 3 days. After 2 weeks, cell
colonies larger than 10 cells were scored under a Nikon
inverted-phase microscope [10].
2.7. Genotyping of Lung Tumor Tissue Samples. Genomic
DNA was isolated from human tumor tissue samples using
the DNeasy kit (Qiagen, Valencia, CA). Primers and probes
for all of the measured SNPs were obtained from the ABI
TaqMan SNP Genotyping Assay (Applied Biosystems), using
the Assay-by-Design service for which we provided the
sequences, or the Assay-on-Demand service when the assays
werealreadydesignedbyAppliedBiosystems.Reactionswere
performed in 5µL volume and contained 10ng DNA, 1x
TaqMan Universal Mastermix (Applied Biosystems), 200nM
ofeachprobe and 900nM ofeach primer. Cycling conditions
on the ABI PRISM 7900HT Sequence Detection System
(Applied Biosystems) were 10min at 95◦C, followed by 40
cycles of 15sec at 95◦C and 1min at 60◦C. After cycling,
the endpoint ﬂuorescence was measured and the ampliﬁed
sequences determined by DNA sequencing analysis. Alleles
were assigned using the SDS 2.1 software (Applied Biosys-
tems).
2.8. Lung Tumor Tissue Sample Clustering Analysis and Heat
Map Generation. Hierarchical clustering analysis was per-
formed on the 50 lung tumor tissue samples to explore
whether the pathway activation proﬁles determined by the
CEER assay and the gene mutational analysis done for
these samples could segregate them into distinct subsets
that are similar to the pathway activation and mutational
signatures of the tumor cell lines. The general construction
of a hierarchical agglomerative classiﬁcation was achieved
by using an algorithm to ﬁnd the two closest objects and
merge them into a cluster, and then ﬁnd and merge the
next two closest points, where a point is either an individual
object or a cluster of objects. A heat map of one-dimensional
hierarchical clustering result was generated in the analysis
to demonstrate the sample clustering structure based on
pathway activation signatures and mutational status.
3. Results
3 . 1 .P r o ﬁ l i n go ft h eA c t i v a t e dK i n a s eP a t h w a y si nT u m o rC e l l
Lines. The activated cell signaling pathways for eight lung
tumor cell lines were proﬁled using the CEER assay. The
assay measured the activated (p-Tyr) HER1, HER2, HER3,4 International Journal of Proteomics
c-MET, IGF-1R, c-Kit, PI3K, and SHC levels in the cells
based on the number of cells being assayed. The tumor
c e l l sw e r ec u l t u r e di np r e s e n c eo f1 0 %F B Sa n dh a r v e s t e d
at about 80% conﬂuence for preparation of cell lysates and
signaling pathway proﬁling. Serial dilutions of tumor cell
lysates equivalent to 10–10,000 cells were assayed, and the
raw data captured on the slides are shown in Figure 1(a) and
a graphic representative of the data is shown in Figure 1(b).
As seen in Figure 1(b),thedose-responsecurvesrepresenting
the level of activation in each RTK pathway is inversely
proportional to the number of cells being assayed. The more
activated the pathway, the less number of cells are needed to
generate the maximal signal. Thus, the relative activation of
the activated pathways can be determined based on the EC50
value of the number of cells being assayed in each pathway
activation curve (see Supplemental Table 2).
As shown in Figure 1(b), each of the eight tumor cell
lines exhibited a distinct RTK activation pattern. The lung
adenocarcinoma cell line, HCC827, exhibited the greatest
number of activated RTK pathways, with HER1, c-MET,
and HER2 being highly activated, PI3K being moderately
activated, and HER3 as well as IGF-1R being lowly activated.
The other adenocarcinoma cell line H1975 showed only
moderate activation of HER2, c-MET, and SHC pathways
and a low activation of the IGF-1R pathway. The remain-
ing adenocarcinoma cell line H1734 exhibited a moderate
activation of the HER1 pathway and a very low activation
of the HER2 and c-MET pathways. By contrast, the adeno-
carcinoma cell line H1993 from a metastatic tumor showed
a very potent activation of the c-MET pathway, with also
a high activation of the HER2 and SHC pathways, and a
moderate activation of the HER3 and HER1 pathways. Both
primaryandmetastaticbronchioalveolarcarcinomacelllines
H358 and H1650 showed a moderate activation of the HER1
and HER2 pathways, with H358 also exhibited a moderate
activation of the c-MET and IGF-1R pathways. The large-cell
carcinoma cell line A549 exhibited a moderate activation of
the HER1 and IGF-1R pathways with a low activation of the
c-METandHER2pathways,whereasthemetastaticlarge-cell
carcinoma cell line H460 showed only a very low activation
of the IGF-1R pathway.
3.2. Inhibition of Activated Signaling Pathways in Tumor
Cell Lines by Kinase Inhibitors. Proﬁling of the eight tumor
cell lines showed that the HER1 and HER2 pathways are
highly activated in the HCC827 cells and thus treatment of
these cells with an irreversible HER1/2 inhibitor BIBW-2992
should be able to block the activation of these pathways.
Indeed, the data presented in Figure 2, showed that a
potent dose-dependent inhibition of the HER1 and HER2
pathways in the HCC827 cells was observed by treatment
with BIBW-2992. Other HER1 and/or HER2 pathway-
activated cell lines, H1975 and H1650, were likewise had
these pathway activations blocked by the treatment with
BIBW-2992. What is remarkable is that the H1975 cell line
harbors the T790M and L858R mutations in the HER1 gene
(information obtained from the Sanger Institute website),
which confer resistance to HER1 kinase inhibitors, Geﬁtinib
and Erlotinib, responded to the irreversible HER1 kinase
inhibitor BIBW-2992. Two other additional HER1 and/or
HER2 pathway-activated cell lines, H358 and H1734, also
hadtheiractivationblockedbytheHER1/2kinaseinhibitors,
GeﬁtinibandLapatinib,respectively.Inthec-METampliﬁed
cellline H1993, activation of this pathway wasblocked by the
treatmentwithPF-2341066,ac-METkinaseinhibitor.Thec-
MET inhibitor also inhibited the HER1 signaling pathway in
this cell line, most likely due to crosstalk between the HER1
and c-MET pathways. Treatment with the IGF-1R kinase
inhibitor BMS-536924 was able to block the activated IGF-
1R pathway exhibited by the A549 and H460 cell lines.
3.3. Inhibition of Tumor Cell Line Proliferation by Kinase In-
hibitors. Since one purpose of this study was to correlate
the activated RTK pathways and gene mutations found in
the tumor cell lines with the appropriate kinase inhibitors
to determine whether treatment with the inhibitors could
inhibit the growth of these cells, the eight tumor cell lines
were treated with the selected kinase inhibitors and the
results shown in Figure 3. As expected, the lung adenocar-
cinoma cell line HCC827, which exhibited highly activated
H E R 1a n dH E R 2p a t h w a y sa sw e l la sH E R 1m u t a t i o n ,
responded exceedingly well to the HER1 inhibitors, Erlotinib
andGeﬁtinib.Inaddition,twootherHER1/2inhibitors,Lap-
atinib and BIBW-2992, were able to inhibit the proliferation
of this cell line. By contrast, the speciﬁc c-MET inhibitor PF-
2341066 (Crizotinib) wasnotabletoinhibit theproliferation
of this cell line even though it exhibited the activated c-
MET pathway. This is not surprising because it has been
shownthatCrizotinibiseﬀectiveintreatingpatientscarrying
the ALK/EML4 fusion gene and this drug response is not
correlated with c-MET ampliﬁcation. Moreover, inhibition
of proliferation by BMS-536924, an IGF-1R inhibitor, in
the HCC827 cells could be due to crosstalk between c-
MET and IGF-1R pathways. The proliferation of two other
HER1 and HER2 pathway-activated adenocarcinoma cell
lines, H1734 and H1975, was also inhibited by Erlotinib.
Moreover, the irreversible HER1/2 kinase inhibitor, BIBW-
2992, was also able to potently inhibit the growth of the
H1975 cell line, which harbored the T790M and L858R
mutations in the HER1 gene and thus rendering the cells
resistant to Geﬁtinib and Lapatinib treatment. In addition,
the IGF-1R inhibitor BMS-536924 was also able to inhibit
the growth of this cell line. In regard to the metastatic
adenocarcinoma cell line H1993, which exhibited a potently
activated c-MET pathway, the c-MET inhibitor PF-2341066
was able to block its proliferation very eﬀectively. What is
more, the downstream MEK inhibitor PD-325901 was also
able to block the proliferation of the H1993 cells whereas
the irreversible HER1/2 inhibitor BIBW-2992 and the PI3K
inhibitor BEZ-235 were able to block the proliferation of
this cell line but only weakly. Proliferation of the carcinoma
cell line H358, which exhibited a moderate activation of the
HER1, HER2, and IGF-1R pathways, was weakly blocked by
the HER1/2 inhibitors, Lapatinib and Geﬁtinib, but the IGF-
1R inhibitor BMS-536924 was able to inhibit its proliferation
more eﬀectively. Surprisingly, growth of the H358 cell lineInternational Journal of Proteomics 5
Figure 1: Continued.6 International Journal of Proteomics
Figure 1: Proﬁling of the activated (p-Tyr) RTK signaling pathways in the lung tumor cell lines. (a) Slide images of the CEER assay
obtained from the eight tumor cell lines (please see the supplemental data and methods for experimental details available online at doi:
10.1155/2011/215496). (b) Graphical representation of the activated (p-Tyr) RTK pathways in the lung tumor cell lines proﬁled by the CEER
assay. The cells were cultured in the presence of 10% FBS in their respective medium until 80% conﬂuence and cell lysates were prepared
in lysis buﬀer. The activation signal was determined from the harvested lysate. In each cell line the activated pathways are shown in RFU
(relative ﬂuorescent units) based on the lysate obtained from the number of cells being assayed.International Journal of Proteomics 7
Figure 2: Inhibition of signaling pathway activation in lung tumor cell lines by kinase inhibitors. Lung tumor cells were cultured in 10% FBS
until reaching ∼80% conﬂuence and then the cells were starved in serum-free medium for overnight, followed by 4-hour treatment with the
inhibitors. Cell lysates were then prepared and used for determination of the pathway activation signals by the CEER assay.
was not inhibited by the c-MET inhibitor PF-2341066, even
though it exhibited a moderately activated c-MET pathway.
Growth of the metastatic carcinoma cell line H1650, which
harbored moderately activated HER1 and HER2 pathways,
was inhibited by the irreversible HER1/2 inhibitor BIBW-
2292. Proliferation of the large-cell carcinoma cell line A549,
which exhibited moderately activated HER1 and IGF-1R
pathways, was inhibited by the PI3K inhibitor BEZ-235 and
bytheIGF-1RinhibitorBMS-536924andweaklybytheMEK
inhibitor PD-325901. Growth of the remaining metastatic
large-cell carcinoma cell line H460, which harbored the
PIK3CA gene mutation and an activated IGF-1R pathway,
was inhibited by the PI3K inhibitor BEZ-235 but weakly
inhibited by the IGF-1R inhibitor BMS-536924.
3.4. Anchorage-Independent Growth Inhibition of Tumor Cell
Lines by Kinase Inhibitors. Since anchorage-independent
growth is a hallmark of transformed cells, we wanted
to ensure that the kinase inhibitors which were able to
strongly block tumor cell proliferation in tissue culture were
also able to inhibit the same tumor cells’ proliferation in
an anchorage-independent manner. As seen in Figure 4,
Erlotinib, which inhibited the growth of HCC827 cells
cultured in anchorage-dependent cell culture plates, was
also able to reduce the size of the cell colonies grown in
agar plates in an anchorage-independent fashion. Similarly,
reduction of cell colony size formation was also observed
by the treatment with the irreversible HER1/2 inhibitor
BIBW-2992 in H1975 and H1650 cells as seen when these
cells were grown in an anchorage-dependent manner. Large
colony formation of H1993 cells, whose proliferation in
tissue culture was potently blocked by treatment with the
c-MET kinase inhibitor PF-2341066, was also inhibited by
treatmentwiththesameinhibitor.Proliferationofcellcolony
size in the H1734 cells was potently blocked by treatment
with the downstream MEK inhibitor PD-325901 as seen
when these cells were grown in cell culture. Likewise, the
IGF-1R kinase inhibitor BMS-536924 was able to reduced8 International Journal of Proteomics
Figure 3:Inhibitionoflungtumorcellgrowthbykinaseinhibitors.Lungtumorcellswereculturedin5%FBSplusincreasingconcentrations
oftheindicated inhibitors,rangingfrom0.01–10µM, for48 hours.Determination of cell proliferationwas performed with the CellTiter-Glo
Luminescent Cell Viability Assay.International Journal of Proteomics 9
Figure 4: Inhibition of anchorage-independent growth of lung tumor cell lines by selected inhibitors. Each selected cell line was treated
with the indicated inhibitor at 0.1µM and 1µM concentrations for two weeks and cell colony size formation was scored under the Nikon
inverted-phase microscope.
cell colony size formation, dose dependently in the H358,
A549 and H460 cells.
3.5. Inhibition of Tumor Cell Line Growth by a Combination
of Two Kinase Inhibitors. Tumor cells often rely on signaling
from multiple pathways and, hence, treating patients with a
singleagentcanseldomeradicatetumorgrowth[11].Acom-
mon clinical practice is to treat patients with combination
therapies. In order to identify therapeutics with synergistic
eﬀects, we selected four tumor cell lines out of the eight and
treated them with a combination of two kinase inhibitors,
one inhibiting the appropriate RTK and the other inhibiting
a downstream signaling pathway. As seen in Figure 5, the
H1975 cells, whose growth was moderately inhibited by
the HER1/2 RTK inhibitor BIBW-2992, but only weakly
inhibited by the downstream MEK inhibitor PD-325901 and
the downstream PI3K inhibitor BEZ-235, responded more
eﬀectively to a combination of BIBW-2992 with either PD-
325901 or BEZ-235 with almost 100% growth inhibition of
this cell line at 10µM concentration whereas a combination
of the two downstream inhibitors, PD-325901 and BEZ-
235, was much less eﬀective. Likewise, combination of PD-
325901 or BEZ-235 with the c-MET inhibitor PF-2341066
was more eﬀective in blocking the proliferation of the H1993
cells, which exhibited a potently activated c-MET pathway,
then by treating this cell line with the c-MET inhibitor
PF-2341066 alone. Interestingly, a combination of both
downstreamkinaseinhibitors,PD-325901andBEZ-235,was
the most eﬀective in blocking the proliferation of this cell
line. In the bronchioalveolar cell line H358, which exhibited
HER1 and HER2 activation, treatment with the HER1
inhibitor Erlotinib in combination with either one of the
two downstream inhibitors, PD-325901 or BEZ-235, showed
synergistic inhibition of cell proliferation. A combination
of the two downstream inhibitors, PD-0325901 and BEZ-
235, was also highly eﬀective. The same phenomenon was
observed in the metastatic bronchioalveolar cell line H1650
when it was treated with the irreversible HER1/2 inhibitor
BIBW-2992 in combination with one of the downstream
inhibitor BEZ-235 or a combination of the two downstream
inhibitors, PD-325901 and BEZ-235.10 International Journal of Proteomics
Figure 5:Inhibitionoflungtumorcellgrowthbyacombinationoftwokinaseinhibitors.Lungtumorcelllineswereculturedin5%FBSplus
increasing concentrations of the indicated single kinase inhibitor or a combination of the two indicated kinase inhibitors. Determination of
cell proliferation was performed with the CellTiter-Glo Luminescent Cell Viability Assay.
3.6.ClusteringofTumorTissueSampleswithTumorCellLines.
Proﬁling of the 50 human lung tissue samples using the
CEER assay revealed distinct activated signaling pathways
in each of the tissue samples as shown in the heat map
in Figure 6(a) (see also Supplemental Table 3). Based on
these results, unsupervised one-dimensional clustering of
the 50 lung tumor tissue samples with the corresponding
cell lines H1993, H1975, HCC827, H1734, H1650, H358,
H460,andA549,couldbeperformedasshowninFigure 6(b)
because a signiﬁcant degree of shared pathway activation
exists between the primary tumor tissue samples and the
tumor cell lines. Clustering of the tumor tissue samples
with their corresponding cell lines provides potential insight
into targeted therapy based on the drug treatment results
obtained from the tumor cell lines.
3.7. Gene Mutation Analysis of Tumor Tissue Samples. Mu-
tation analysis of three frequently mutated genes (KRAS,
P53, and STK11) in 50 human lung tissue samples further
supported the clustering of human tumor samples into the
cell line groups (see Supplemental Table 3). For example,
patient samples LC16, LC44, and LC23 were originally
aligned with tumor cell line H358 based on CEER assay
proﬁling. This alignment was supported by the ﬁnding that
these three tissue samples also harbored the G34A and G37T
KRASmutationsaswasfoundintheH358cellline.Similarly,
the original alignment of patient samples LC45 with cell line
H1734 and LC21 with cell line A549 was substantiated by
ﬁnding the same G34A and G37T KRAS mutations in both
patient samples and cell lines. In addition, alignment of the
patient sample LC15 with cell line H460 is supported by
the ﬁnding of the A183T KRAS mutation in both patient
sample and cell line. Likewise, the alignment of patient
samples LC6, LC31, and LC13 with cell lines H1975 and
H1734 was substantiated by the ﬁnding of the C726G and
G818T P53, mutations in both patient samples and cell lines.International Journal of Proteomics 11
(a) (b)
Figure 6: (a) Heat Map representing the activated signaling pathways found in the 50 lung tumor tissue samples and eight lung tumor cell
lines. Each row constitutes all the pathway markers determined from an individual tumor sample organized in color columns. Green and red
denote markers that are present at lower and higher levels, respectively. (b) Clustering of the 50 lung tumor samples with the corresponding
lung tumor cell lines based on the similarities in the markers between the tissue samples and the cell lines.
Also, the alignment of patient samples LC32 and LC23 with
cell line H1650 was supported by the ﬁnding of the same
P53 mutations in both patient samples and cell line. Lastly,
the alignment of patient sample LC25 with the H1993 cell
line was supported by the ﬁnding of the C109T and G595T
STK11 mutations in both patient sample and cell line. Thus,
clustering of the patient tissue samples with the tumor cell
linesbasedonmutationalstatusoftheKRAS,P53andSTK11
genes was also consistent with the clustering based on the
RTK pathway signatures.
4. Discussion
Current lung cancer treatments are less than optimal, with a
mean survival of less than one year for advanced lung cancer
patients, regardless of treatment regimen [2]. Emerging new
treatment modalities are generally targeted to inhibit speciﬁc
tyrosinekinasesactivatedinthetumorcellsthroughbasically
two independent approaches [3]. The ﬁrst approach is to
use a highly speciﬁc monoclonal antibody to target the
membrane growth factor receptor kinase that is responsible
for tumor cell growth, and the resulting antibody/antigen
complex invokes the host immune system to kill the tumor
cells. This approach is exempliﬁed by the treatment of
HER2 receptor-positive breast cancer with Herceptin, a
humanized monoclonal antibody against this receptor [4].
However, the high cost of monoclonal antibody drugs could
be a disadvantage for this approach. The second approach
is to develop cell-penetrating small organic molecules that
target the speciﬁc tyrosine kinases in the signaling pathways
of the tumor cells. This approach is best exempliﬁed by the
use of Gleevec to block the activation of the BCR-ABL fusion
kinase in chronic myelogenous leukemia [5]. The design and
synthesis of small molecule tyrosine kinase inhibitors have
been greatly facilitated by the availability of crystal structures
for the tyrosine kinases in the past decade and eﬀective
kinase inhibitors have thus been produced by many large
and small pharmaceutical companies. Nevertheless, without
prior knowledge of the activated kinase signaling pathways
responsibleforpropagatingandmetastasisofthetumorcells,
it is not possible to apply the targeted therapy approach with
the available kinase inhibitors. Therefore, we have selected a
panel of eight lung tumor cell lines that harbored the most
frequently detected gene mutations: P53, KRAS, STK11,
and HER1 as representative examples that cover the major
human lung cancer subtypes.
Mutation analysis has provided valuable information
in guiding targeted therapy for cancer patients. A good
example is found in cancer patients who carry a KRAS gene
mutation because these patients have been shown to be
nonresponsive to anti-HER1 therapeutics. Therefore, KRAS
mutationtestingisbecomingroutinelyperformedinpatients
who are being considered for anti-HER1 therapy with either
CetuximaborPanitumumabinEuropeandtheUnitedStates
[12, 13]. Our current study further conﬁrmed an important
role of gene mutation analysis in guiding the use of drugs12 International Journal of Proteomics
to treat lung cancers. For example, it has been reported
that cancers from patients with lung adenocarcinoma that
harbored mutations within the tyrosine kinase domain of
the HER1 gene often responded initially to TKI drugs such
as Geﬁtinib and Erlotinib [14, 15] but usually developed
drug-resistance later [16–18]. Indeed, the HCC827, H1975,
and H1650 lung tumor cell lines employed in this study
harbored the HER1 gene mutation and they were found to
be sensitive to HER1 inhibitor treatment. By contrast, KRAS
gene mutation is associated with resistance to HER1 tyrosine
kinase inhibitors [19, 20]. This phenomenon is substantiated
by our ﬁnding that the A549 and H460 cells, which harbored
the KRAS mutated gene, did not respond to treatment with
HER1 inhibitors but they are sensitive to the downstream
PI3K inhibitor BEZ-235.
Although targeted therapy based on association of
somatic mutation analysis and drug sensitivity has greatly
facilitated lung cancer treatment, the proﬁling of oncogenic
signal transduction pathways in human tumor cells and
tissues oﬀers yet another complementary approach to guide
therapeutic treatment [21–25]. Traditional signaling path-
wayproﬁlingintumortissuesamplesbyimmunohistochem-
istry (IHC) staining or Western blotting methods are neither
quantitative nor sensitive enough to have utility when only
smallamountoftumortissuesamplesisavailable.TheCEER
assay is an assay that we have developed to overcome the
low sensitivity and speciﬁcity issues associated with these
traditional methods. The CEER assay uses a multiplexed,
proximity-based, collaborative immunoassay platform that
can provide clinical information on a limited amount of
tissue samples with high sensitivity and speciﬁcity. The
principle of the assay is based on the formation of a unique
immunocomplex that requires the colocalization of two
detecting antibodies against a target protein once the protein
is captured on the microarray surface. It is the formation of
this complex that enables the generation of a highly speciﬁc
andsensitivesignaltorevealtheactivationstatusofthetarget
protein. We have compared CEER with the conventional
IHC/FISH and Western blotting and found that the CEER
assay provided more quantitative information in regard to
the oncogenic kinases [26]. Using this assay, the activated
HER1, HER2, HER3, c-MET, IGF-1R, PI3K, and SHC
pathways present in the eight lung tumor cell lines as well as
the 50 human lung tumor tissue samples were proﬁled. Cell
lines that exhibited one or more of these activated pathways
were treated with the corresponding kinase inhibitors and
the results demonstrated that this matching approach is
eﬀective in inhibiting the pathway activation and growth
of these cell lines under both anchorage-dependent and
anchorage-independent culture conditions. Moreover, in
those cell lines in which signiﬁcant growth inhibition could
not be achieved with a single kinase inhibitor treatment
(H1993, H358, and H1650), a combination treatment with
two kinase inhibitors, one targeting the RTK and the other
targeting a downstream kinase, was eﬀective in blocking
their proliferation. However, we noted that there was no
direct correlation between the IC50 value of the drug with
the level of the corresponding pathway activation because
we only measured a subset of pathway biomarkers. There
might be other important pathways which may contribute to
tumor growth. Another aspect is that the mutational status
of tumor cells also plays an important role in driving the
tumorgrowth.Nevertheless,characterizationoftheactivated
signaling pathways and mutational status as well as their cell
growth inhibition by kinase inhibitors in the lung tumor
cell lines could facilitate the target-focused treatment of lung
cancers.
Pathway proﬁling using the CEER assay and gene
mutational analysis of the 50 tumor tissues collected from
lung cancer patients clearly showed some similarities in
the biomarkers between the lung tumor tissue samples and
tumor cell lines. Therefore, the panel of pathway biomarkers
and mutated genes can discriminate and cluster diﬀerent
tumor tissue samples with the corresponding tumor cell
lines in both supervised and unsupervised clustering analysis
and this information could be used to guide treatment
options based on the drug sensitivity of the tumor cell lines.
However, it is important to interpret the data with caution
due to the small sample size of the tumor tissue samples.
Prospective validation studies with suﬃcient sample size and
enough analytical power are essential to substantiate the
role of these pathway biomarkers in cancer diagnosis and
treatment. The ultimate validation of this approach is the
patient’s response to drug treatment based on the biomarker
prediction. Irrespective of the slow progress made towards
curing cancer, we have gained much knowledge through
translational research by using new molecular and biological
technology.Webelievethatthecontinuinggaininknowledge
of lung cancer biology will provide the foundation for im-
provement in lung cancer treatment.
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